126 related articles for article (PubMed ID: 32387312)
1. Functional similarity of modified cascade impactor to deposit drug particles on cells.
Kumar V; Bariwal J; Narang AS; Tso J; Cheong J; Mahato RI
Int J Pharm; 2020 Jun; 583():119404. PubMed ID: 32387312
[TBL] [Abstract][Full Text] [Related]
2. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
Bur M; Huwer H; Muys L; Lehr CM
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
[TBL] [Abstract][Full Text] [Related]
3. Respiratory Tract Deposition of HFA-Beclomethasone and HFA-Fluticasone in Asthmatic Patients.
Leach CL; Kuehl PJ; Chand R; McDonald JD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):127-33. PubMed ID: 26061801
[TBL] [Abstract][Full Text] [Related]
4. Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI).
Rowland M; Cavecchi A; Thielmann F; Kulon J; Shur J; Price R
Pharm Res; 2018 Nov; 36(1):15. PubMed ID: 30478630
[TBL] [Abstract][Full Text] [Related]
5. Validation of a cell integrated next-generation impactor to assess in vitro drug transport of physiologically relevant aerosolised particles.
Wong CYJ; Cuendet M; Spaleniak W; Gholizadeh H; Marasini N; Ong HX; Traini D
Int J Pharm; 2022 Aug; 624():122024. PubMed ID: 35843365
[TBL] [Abstract][Full Text] [Related]
6. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.
Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC
AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549
[TBL] [Abstract][Full Text] [Related]
7. Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate.
Kumar V; Sethi B; Yanez E; Leung DH; Ghanwatkar YY; Cheong J; Tso J; Narang AS; Nagapudi K; Mahato RI
Int J Pharm; 2022 Mar; 615():121470. PubMed ID: 35041913
[TBL] [Abstract][Full Text] [Related]
8. Development of a size-dependent aerosol deposition model utilising human airway epithelial cells for evaluating aerosol drug delivery.
Cooney D; Kazantseva M; Hickey AJ
Altern Lab Anim; 2004 Dec; 32(6):581-90. PubMed ID: 15757496
[TBL] [Abstract][Full Text] [Related]
9. In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers.
Haghi M; Traini D; Young P
Pharm Res; 2014 Jul; 31(7):1779-87. PubMed ID: 24549816
[TBL] [Abstract][Full Text] [Related]
10. Design and pharmaceutical applications of a low-flow-rate single-nozzle impactor.
Wang H; Bhambri P; Ivey J; Vehring R
Int J Pharm; 2017 Nov; 533(1):14-25. PubMed ID: 28939463
[TBL] [Abstract][Full Text] [Related]
11. Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?
Ong HX; Traini D; Loo CY; Sarkissian L; Lauretani G; Scalia S; Young PM
Eur J Pharm Biopharm; 2015 Jun; 93():320-7. PubMed ID: 25930239
[TBL] [Abstract][Full Text] [Related]
12. Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler.
Haghi M; Traini D; Postma DS; Bebawy M; Young PM
Respirology; 2013 Nov; 18(8):1197-201. PubMed ID: 23796052
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models.
Acosta MF; Muralidharan P; Meenach SA; Hayes D; M-Black S; Mansour HM
Curr Pharm Des; 2016; 22(17):2522-31. PubMed ID: 26831643
[TBL] [Abstract][Full Text] [Related]
14. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
Van Holsbeke C; De Backer J; Vos W; Marshall J
Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer.
Waldrep JC; Berlinski A; Dhand R
J Aerosol Med; 2007; 20(3):310-9. PubMed ID: 17894537
[TBL] [Abstract][Full Text] [Related]
16. Particle Size Measurements from Orally Inhaled and Nasal Drug Products.
Mitchell JP
J Aerosol Med Pulm Drug Deliv; 2021 Dec; 34(6):325-345. PubMed ID: 34860563
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI).
Mohan M; Lee S; Guo C; Peri SP; Doub WH
AAPS PharmSciTech; 2017 Jul; 18(5):1585-1594. PubMed ID: 27624069
[TBL] [Abstract][Full Text] [Related]
18. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3).
Borchard G; Cassará ML; Roemelé PE; Florea BI; Junginger HE
J Pharm Sci; 2002 Jun; 91(6):1561-7. PubMed ID: 12115854
[TBL] [Abstract][Full Text] [Related]
19. A methodology to study impactor particle reentrainment and a proposed stage coating for the NGI.
Rissler J; Asking L; Dreyer JK
J Aerosol Med Pulm Drug Deliv; 2009 Dec; 22(4):309-16. PubMed ID: 19415989
[TBL] [Abstract][Full Text] [Related]
20. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs.
Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P
Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
